Type I diabetes is characterized by the gradual loss of β cells in the pancreas leading to insulin deficiency, hyperglycemia, and if left untreated, death. Since the 1920’s Type I diabetes has been treated with multiple daily injections of insulin in an attempt to restore glucose metabolism and stave off ketoacidosis - the life-threatening consequence of chronic hyperglycemia. While insulin injections have allowed millions of people to successfully live with Type I diabetes, it is by no means a perfect treatment. Multiple daily injections and the short half-life of insulin combine to cause daily bouts of hypoglycemia and hyperglycemia, which can cause multiple detrimental sequelae including microvascular damage, nerve damage, fat buildup/obesity, and cardiovascular disease (Smith-Marsh and Zeller 2017). Thus, Type I diabetics have been waiting for a new and better therapy to be developed.